#USA #San Diego #Clinical Trials #Aethlon Medical #Hemopurifier

Aethlon Medical's Q1 Fiscal 2027 Update

Aethlon Medical, Inc., a notable player in the clinical-stage medical therapeutic sector, has recently disclosed its financial performance for the first quarter of fiscal 2027, which ended on June 30, 2026. In this period, the company made significant strides in both its financial standing and research timeline, particularly regarding its Hemopurifier® program.

Financial Highlights

• - Cash Position: As of June 30, 2026, Aethlon's cash and cash equivalents were approximately $4.9 million. Following the quarter, the company secured about $4.0 million from a public offering of common stock, which they believe will adequately fund operations for at least the next twelve months.
• - Operating Expenses: The company's consolidated operating expenses showed a reduction of 11.9% compared to the same quarter a year ago, bringing them down to around $1.6 million from $1.8 million. This decrease can be attributed to lower professional fees and reduced costs related to general administration and preclinical research efforts.
• - Operating Loss: The operating loss for the quarter was approximately $1.6 million, a decline from the losses recorded in the previous year's quarter.

Clinical Developments

Aethlon Medical's ongoing clinical studies have been a focal point of its operations this quarter:

1. Oncology Study: The company made headlines by treating the first participant in the third cohort of its Phase 1 oncology study in Australia. Preliminary results from earlier cohorts suggest a promising pattern regarding the reduction of tumor-derived extracellular vesicles and microRNAs associated with cancer progression. These early biomarker signals hint at improvements in immune function that may relate to potential responses to immunotherapy, though comprehensive evaluations will follow the study's completion.

2. Long COVID Research: Additionally, Aethlon Medical achieved a significant milestone with their research on Long COVID, as their manuscript detailing extracellular vesicle characteristics in affected patients was accepted for publication in the International Journal of Molecular Sciences. The findings indicate that extracellular vesicles isolated from individuals with Long COVID effectively bind to the GNA affinity resin used in the Hemopurifier, further supporting the device's investigational applications.

Looking Ahead

In terms of future endeavors, James Frakes, the CEO and CFO of Aethlon Medical, expressed optimism about the company's trajectory. He noted that the recent advancements in clinical trials and research underscore their commitment to advancing the Hemopurifier® technology and exploring its implications in oncology and infectious diseases.

The Hemopurifier® itself is a cutting-edge investigational medical device designed to filter enveloped viruses and tumor-derived extracellular vesicles from the bloodstream, thereby addressing critical challenges in treating advanced cancers and life-threatening viral infections. This device is especially noteworthy due to its ability to target specific components in the bloodstream, a feature that has garnered significant interest within the medical community.

Conference Call Details

On August 13, 2026, Aethlon plans to host a conference call at 4:30 p.m. ET to discuss the financial outcomes and recent corporate developments. This call promises to provide further insights into the company's future directions and ongoing clinical progress.

For interested participants, registration for the call can be completed online, with options available for those without internet access.

Conclusion

Aethlon Medical's recent updates convey resilience and strategic movement within the clinical landscape. As they continue to evaluate the Hemopurifier®'s efficacy and advance their research initiatives, the coming months will be pivotal in determining the outcomes of their ongoing trials and the broader implications for patient care.